Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 290, pseudogene (RNU6-290P) is classified as a pseudogene of the U6 small nuclear RNA family. Pseudogenes are genomic DNA sequences similar to normal genes but typically non-functional; they generally do not encode functional proteins or RNAs and do not participate in canonical biological processes such as catalysis, signaling, or direct molecular interactions. The canonical U6 small nuclear RNA (snRNA) is a core component of the spliceosome, involved in pre-mRNA splicing. However, RNU6-290P itself is a non-coding, non-functional relabeled genomic element believed to have arisen from retrotransposition or duplication of the active U6 gene, but lacking the elements necessary for normal expression and function. There is no current evidence that RNU6-290P serves as a therapeutic target, biomarker, or is implicated in disease processes. Its primary significance is as an annotated pseudogene in the genome. Its locus is located at chromosome 1q24.3. This gene entry is a pseudogene, not a functional protein, non-coding RNA, receptor, enzyme, or other conventional drug target class. It should not be treated as a therapeutic target, nor as a biomarker, unless future research indicates functional activity, which is currently lacking in all reputable databases and literature. If further clarification is needed on canonical U6 snRNA function, research should instead focus on U6 spliceosomal RNA, not pseudogene variants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 290, pseudogene (RNU6-290P).